Liver pathology in porphyria cutanea tarda;Patologie watroby w przebiegu porfirii skórnej póź nej

Advances in Clinical and Experimental Medicine

Volumn 13, Issue 5, 2004, Pages 833-838

  Dziemianko, Ilona ^a   Piszko, Paweł ^a   Simon, Krzysztof ^a   Gładysz, Andrzej ^a  

^a Katedra i Klinika Chorob Zakaznych   (Poland)

Author keywords

HCV; Iron metabolism; Liver; Porphyria cutanea tarda

Indexed keywords

ESTROGEN; HEPATITIS C ANTIBODY; UROPORPHYRINOGEN DECARBOXYLASE;

ALCOHOL CONSUMPTION; DISORDERS OF METAL METABOLISM; ENZYME ACTIVITY; HUMAN; LIVER DISEASE; METABOLIC DISORDER; PATHOLOGY; PORPHYRIA CUTANEA TARDA; REVIEW; VIRUS;

HEPATITIS C VIRUS;

EID: 10644245808     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Bulaj ZJ, Phillips JD, Ajioka RS et al.: Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000, 1, 95 (5), 1565.
2. Kappas A, Sassa G, Galbraith RA, Nordmann Y: The porphyrias. In: The molecular and metabolic basis of inherited disease. Eds.: Scriver CR, Beaude AL, Sly WS, Valle D. McGraw-Hill, New York 1995, 7th ed. 50, 2103.
3. Sweeney GD: Porphyria cutanea tarda, or the uroporphyrinogen decarboxylase deficiency diseases. Clin Biochem 1986, 19, 3.
4. Navas S, Bosch O, Castillo I et al.: Porphyria cutanea tarda and hepatitis C virus and B viruses infection: a retrospective study. Hepatology 1995, 21, 279.
5. Quecedo L, Costa J, De Salamanca RE: The role of hepatitis C virus in the liver disease of porphyria cutanea tarda. Med Clin 1996, 106, 321.
6. Tsukazaki N, Watanabe M, Irifune H: Porphyria cutanea tarda and hepatitis C virus infection. Br J Dermatol 1998, 138 (6), 1015.
7. Falkiewicz B, Dabrowska E, Jabłońska-Kaszewska I: Porfiria skórna późna - nowe spojrzenie na patogeneze i terapie. Wiad Lek 1997, 50, 106.
8. Kuszewski K: Wirusowe zapalenie watroby B oraz typu C w roku 1997. Przegl Epidemiol 1999, 53, 75.
9. Martinelli A, L, Villanova MG, Roselino AM et al.: Abnormal uroporphyrin levels in chronic hepatitis C virus infection. J Clin Gastroenterol 1999, 29, 327.
10. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N et al.: Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998, 27 (6), 1661.
11. Armas-Merino R, Wolff CF, Parraguez A, Ramon-Soto JH: Excrecion de porfirinas e infection por virus C de la hepatitis. Rev Med Chil 1997, 125, 279.
12. Stolzel U, Kostler E, Koszka C et al.: Low prevalence of hepatitis C virus infection in porphyria cutanea tarda. Histopathology 1995, 21, 1500.
13. Moran MJ, Fontanellas A, Brudieux E et al.: Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus infection. Hepatology 1998, 27, 584.
14. Fargion S, Fracanzani AL, Romano R et al.: Genetic hemochromatosis in Italian patients with porphyria cutanea tarda: possible explanation for iron overload. J Hepatol 1996, 24, 564.
15. Cortes JM, Oliva H, Paradinas FJ, Fernandes-Guio C: The pathology of the liver in porphyria cutanea tarda. Histopathology 1980, 4, 471.
16. Martinelli AL, Zago MA, Roselino AM et al.: Porphyria cutanea tarda in Brazilian patients: association with hemochromatosis C282Y mutation and hepatitis C virus infection. Am J Gastroenterol 2000, 95 (12), 3516.
17. Malina L, Arenberger P, Karcikova J: Frekvence virove hepatitidy C u nemocnych pozdni kozni porfyrii (PCT). Cas Lek Cesk 1994, 133, 599.
18. Francis JE, Smith AG: Polycyclic aromatic hydrocarbons cause hepatic porphyria in iron-loaded CS7 BL/10 mice: comparsion of uroporphyrinogen decarboxylase inhibition with induction of alkoxyphenoxazone dealkylations. Biochem Biophys Res Common 1987, 146, 13.
19. De Matteis F: Role of iron in the hydrogen peroxide-dependent oxidation of hexahydroporphyrins (porphyrinogens): a possible mechanism for the exacerbation by iron of hepatic uroporphyria. Mol Pharmacol 1988, 33, 463.
20. Bonkovsky HL, Poh-Fitzpatrick M, Tattrie C, DiBisceglie A: Porphyria cutanea tarda and hepatitis C in USA. Hepatology 1996, 24, 1440.
21. Elder GH: Porphyria cutanea tarda: a multifactorial disease. Rec Adv Dermatol 1990, 8, 55.
22. Linet MS, Gridley G, Nyren O et al.: Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol 1999, 149 (11), 1010.
23. Christiansen L, Bygum A, Jensen A et al.: Uroporphyrinogen decarboxylase gene mutations in Danish patients with porphyria cutanea tarda, Scand J Clin Lab Invest 2000, 60 (7), 611.
24. Dabrowska E, Jabłońska-Kaszewska I, Bielawski K, Podlaska M, Falkiewicz B: Porphyria cutanea tarda, hepatitis C virus and selected symptoms of cholestasis. Med Sci Monit 2001, 7, Suppl. 1, 185.
25. Dabrowska E, Jabłońska-Kaszewska I, Łukasiak J, Dorosz A: Żelazo, miedź, cynk i magnez w surowicy chorych z porfiria skórna późna. Hepatol Pol 1995, 2, 21.
26. Dabrowska E, Jabłońska-Kaszewska I, Falkiewicz B: Effect of high fiber vegetable-fruit diet on the activity of liver damage and serum iron level in porphyria cutanea tarda (PCT). Med Sci Monit 2001, 7, Suppl. 1, 282.
27. Siegel LB, Veber BB: Porphyria cutanea tarda remission. Ann Intern Med 1994, 121, 308.
28. Furuta M, Kaito M, Gabazza E et al.: Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea. tarda, but with a transient in HCV RNA levels. J Gastroenterol 2000, 35(1), 60.
29. Kishimoto Y, Nishimuki E, Syabana N et al.: Clinical course of porphyria cutanea tarda diagnosed after interferon therapy in a case of chronic hepatitis C. Porphyrins 1998, 7, 325.
30. Bonkovsky HL, Barnard GF: The porphyrias. Curr Treat Options Gastroenterol 2000, 3, 487.